About Dermira (NASDAQ:DERM)
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Industry, Sector and Symbol
Trailing P/E Ratio-1.23641136357152
Forward P/E Ratio-1.95
Sales & Book Value
Annual Sales$4.54 million
Price / Sales83.82
Price / CashN/A
Book Value$3.59 per share
Price / Book2.53
Return on Equity-62.07%
Return on Assets-29.13%
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira Inc (NASDAQ:DERM) posted its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.09. The biopharmaceutical company earned $1.34 million during the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. View Dermira's Earnings History.
Where is Dermira's stock going? Where will Dermira's stock price be in 2018?
7 brokerages have issued 12-month price targets for Dermira's stock. Their forecasts range from $19.00 to $48.00. On average, they expect Dermira's stock price to reach $32.71 in the next year. View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (3/16/2018)
- 2. Mizuho analysts commented, "We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18." (2/23/2018)
- 3. Cantor Fitzgerald analysts commented, "We received a lot of questions regarding DERM’s stock strength on Friday, Jan. 12 (stock closed up 2.77% and was up ~9% intraday versus S&P 500, which closed up 0.67%)." (1/15/2018)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include ProMetic Life Sciences (PFSCF), Anika Therapeutics (ANIK), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Coherus Biosciences (CHRS), Aduro BioTech (ADRO), Urogen Pharma (URGN), Novavax (NVAX), Deciphera Pharmaceuticals (DCPH), Adamas Pharmaceuticals (ADMS), ANI Pharmaceuticals (ANIP), Abeona Therapeutics (ABEO), Rocket Pharmaceuticals (RCKT), Voyager Therapeutics (VYGR), Inflarx (IFRX), ChemoCentryx (CCXI), Menlo Therapeutics (MNLO) and Uniqure (QURE).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder (Age 65)
- Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder (Age 40)
- Luis C. Pena, Co-Founder, Chief Development Officer (Age 54)
- Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer (Age 48)
- Lori Lyons-Williams, Chief Commercial Officer (Age 40)
- Eugene Andrew Bauer M.D., Founder, Chief Medical Officer, Director (Age 74)
- Frederick B. Craves Ph.D., Lead Independent Director (Age 70)
- David E. Cohen M.D., Independent Director (Age 52)
- Matthew K. Fust, Independent Director (Age 52)
- Mark D. McDade, Independent Director (Age 61)
Has Dermira been receiving favorable news coverage?
News headlines about DERM stock have trended somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dermira earned a news sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Dermira's major shareholders?
Dermira's stock is owned by many different of institutional and retail investors. Top institutional investors include
WELLINGTON MANAGEMENT GROUP LLP
(10.50%), BlackRock Inc. (9.34%),
PRUDENTIAL FINANCIAL INC
(2.30%), Jennison Associates LLC (2.33%), Millennium Management LLC (2.16%) and Franklin Resources Inc. (2.14%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Which major investors are selling Dermira stock?
DERM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Deutsche Bank AG, Tekla Capital Management LLC, Nicholas Investment Partners LP, BlackRock Inc., Wells Fargo & Company MN, Guggenheim Capital LLC and Iguana Healthcare Management LLC. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.
Which major investors are buying Dermira stock?
DERM stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc., Emerald Advisers Inc. PA, Opaleye Management Inc., Private Capital Advisors Inc., Schwab Charles Investment Management Inc., AWM Investment Company Inc. and Rock Springs Capital Management LP. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $9.10.
How big of a company is Dermira?
Dermira has a market capitalization of $380.58 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. Dermira employs 162 workers across the globe.
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (DERM)MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dermira (NASDAQ:DERM) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Hold||Hold|
|Consensus Rating Score: ||2.71||2.50||2.33||2.33|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$32.71||$42.17||$41.00||$44.40|
|Price Target Upside: ||259.50% upside||56.40% upside||53.96% upside||68.89% upside|
Dermira (NASDAQ:DERM) Consensus Price Target History
Dermira (NASDAQ:DERM) Analyst Ratings History
(Data available from 3/18/2016 forward)
Dermira (NASDAQ:DERM) Earnings History and Estimates Chart
Dermira (NASDAQ DERM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/22/2018||Q4 2017||($1.25)||($1.34)||$1.10 million||$1.34 million||View||N/A|
|11/6/2017||Q3 2017||($1.12)||($1.21)||$1.05 million||$1.07 million||View||N/A|
|8/7/2017||Q2 2017||($0.89)||($0.93)||$1.00 million||$1.07 million||View||N/A|
|5/8/2017||Q1 2017||($0.86)||($0.79)||$1.07 million||View||N/A|
|2/28/2017||Q4 2016||($0.93)||($0.21)||$22.47 million||View||Listen|
Dermira (NASDAQ:DERM) Earnings Estimates
2018 EPS Consensus Estimate: ($4.61)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com
Dermira (NASDAQ DERM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 94.93%
Dermira (NASDAQ DERM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/1/2018||David E Cohen||Director||Sell||600||$25.85||$15,510.00|| |
|3/1/2018||Eugene A Bauer||Insider||Sell||500||$25.32||$12,660.00|| |
|2/1/2018||David E Cohen||Director||Sell||600||$28.87||$17,322.00||30,282|| |
|2/1/2018||Eugene A Bauer||Insider||Sell||3,000||$28.55||$85,650.00||5,802|| |
|1/2/2018||Christopher M Griffith||SVP||Sell||18,458||$27.05||$499,288.90|| |
|1/2/2018||David E Cohen||Director||Sell||600||$28.03||$16,818.00|| |
|1/2/2018||Eugene A Bauer||Insider||Sell||3,000||$27.07||$81,210.00||5,802|| |
|12/18/2017||Eugene A. Bauer||Insider||Sell||3,000||$27.34||$82,020.00|| |
|12/13/2017||Thomas G. Wiggans||CEO||Sell||5,000||$27.51||$137,550.00|| |
|12/1/2017||David E Cohen||Director||Sell||600||$25.49||$15,294.00|| |
|11/2/2017||Thomas G. Wiggans||CEO||Sell||5,000||$27.52||$137,600.00|| |
|11/1/2017||David E Cohen||Director||Sell||600||$26.82||$16,092.00|| |
|10/11/2017||Eugene A Bauer||Insider||Sell||7,500||$30.04||$225,300.00|| |
|10/10/2017||Thomas G Wiggans||CEO||Sell||5,000||$27.52||$137,600.00|| |
|10/2/2017||David E Cohen||Director||Sell||600||$26.99||$16,194.00||32,682|| |
|9/18/2017||Thomas G. Wiggans||CEO||Sell||9,500||$27.51||$261,345.00|| |
|9/1/2017||David E Cohen||Director||Sell||600||$23.56||$14,136.00||33,282|| |
|8/28/2017||David E Cohen||Director||Sell||600||$23.81||$14,286.00||33,882|| |
|8/14/2017||Fred B Craves||Director||Buy||30,000||$23.03||$690,900.00|| |
|8/1/2017||Thomas G. Wiggans||CEO||Sell||500||$27.58||$13,790.00|| |
|7/5/2017||Eugene A Bauer||Insider||Sell||2,500||$30.00||$75,000.00|| |
|7/3/2017||Thomas G. Wiggans||CEO||Sell||5,000||$29.06||$145,300.00|| |
|6/20/2017||Eugene A Bauer||Insider||Sell||2,500||$30.01||$75,025.00|| |
|6/2/2017||Thomas G. Wiggans||CEO||Sell||5,000||$27.52||$137,600.00|| |
|5/15/2017||Christopher M. Griffith||SVP||Sell||1,312||$27.07||$35,515.84|| |
|4/17/2017||Christopher M. Griffith||SVP||Sell||1,303||$33.97||$44,262.91|| |
|4/3/2017||Eugene A Bauer||Insider||Sell||2,500||$33.53||$83,825.00|| |
|4/3/2017||Thomas G Wiggans||CEO||Sell||8,000||$33.49||$267,920.00||14,468|| |
|4/3/2017||William R Ringo||Director||Sell||500||$34.03||$17,015.00||500|| |
|3/15/2017||Christopher M. Griffith||SVP||Sell||1,303||$35.79||$46,634.37|| |
|3/1/2017||Eugene A Bauer||Insider||Sell||2,500||$33.61||$84,025.00|| |
|3/1/2017||Thomas G Wiggans||CEO||Sell||11,000||$33.54||$368,940.00||17,468|| |
|3/1/2017||William R Ringo||Director||Sell||500||$35.09||$17,545.00||500|| |
|2/15/2017||Christopher M. Griffith||SVP||Sell||1,303||$30.79||$40,119.37|| |
|2/15/2017||William R Ringo||Director||Sell||500||$32.00||$16,000.00||500|| |
|2/14/2017||Eugene A Bauer||Insider||Sell||1,505||$30.00||$45,150.00|| |
|2/1/2017||Eugene A Bauer||Insider||Sell||995||$30.00||$29,850.00|| |
|1/17/2017||Christopher M. Griffith||VP||Sell||1,303||$29.11||$37,930.33|| |
|1/4/2017||Thomas G Wiggans||CEO||Sell||8,000||$31.06||$248,480.00||11,468|| |
|1/4/2017||William R Ringo||Director||Sell||500||$32.00||$16,000.00||500|| |
|1/3/2017||Eugene A Bauer||Insider||Sell||2,500||$30.07||$75,175.00|| |
|12/16/2016||William R Ringo||Director||Sell||125||$32.00||$4,000.00||125|| |
|12/15/2016||Christopher M. Griffith||VP||Sell||1,303||$30.70||$40,002.10|| |
|12/14/2016||Eugene A Bauer||Insider||Sell||2,500||$30.36||$75,900.00|| |
|12/1/2016||Thomas G Wiggans||CEO||Sell||11,000||$30.80||$338,800.00|| |
|12/1/2016||William R Ringo||Director||Sell||375||$32.00||$12,000.00||375|| |
|11/9/2016||Andrew Guggenhime||CFO||Sell||4,100||$35.02||$143,582.00||9,216|| |
|11/9/2016||William R Ringo||Director||Sell||500||$32.30||$16,150.00||500|| |
|11/1/2016||Thomas G Wiggans||CEO||Sell||11,000||$31.19||$343,090.00|| |
|10/17/2016||Christopher M Griffith||VP||Sell||1,303||$32.33||$42,125.99||45,165|| |
|10/11/2016||Andrew Guggenhime||CFO||Sell||10,900||$34.34||$374,306.00||16,016|| |
|10/3/2016||Thomas G Wiggans||CEO||Sell||11,000||$34.60||$380,600.00|| |
|10/3/2016||William R Ringo||Director||Sell||500||$34.25||$17,125.00||500|| |
|9/19/2016||Andrew Guggenhime||CFO||Sell||15,000||$35.01||$525,150.00||20,116|| |
|9/15/2016||Christopher M Griffith||VP||Sell||1,303||$33.26||$43,337.78||45,165|| |
|9/12/2016||Andrew Guggenhime||CFO||Sell||10,000||$32.53||$325,300.00||15,116|| |
|9/1/2016||Thomas G Wiggans||CEO||Sell||11,000||$31.63||$347,930.00|| |
|9/1/2016||William R Ringo||Director||Sell||500||$32.00||$16,000.00||500|| |
|8/15/2016||Christopher M Griffith||VP||Sell||1,303||$31.75||$41,370.25||44,941|| |
|8/11/2016||Andrew Guggenhime||CFO||Sell||10,000||$31.02||$310,200.00||14,375|| |
|8/1/2016||Eugene A Bauer||Insider||Sell||2,500||$33.18||$82,950.00|| |
|8/1/2016||Thomas G Wiggans||CEO||Sell||11,000||$33.19||$365,090.00|| |
|8/1/2016||William R Ringo||Director||Sell||500||$33.65||$16,825.00||500|| |
|7/15/2016||Christopher M Griffith||VP||Sell||1,303||$30.02||$39,116.06||44,941|| |
|7/11/2016||Andrew Guggenhime||CFO||Sell||10,000||$30.15||$301,500.00||14,375|| |
|7/5/2016||Thomas G Wiggans||CEO||Sell||11,000||$29.62||$325,820.00|| |
|7/1/2016||Eugene A Bauer||Insider||Sell||2,500||$29.48||$73,700.00|| |
|6/23/2016||Luis C Pena||Insider||Sell||10,000||$30.01||$300,100.00||14,653|| |
|6/15/2016||Luis C Pena||Insider||Sell||10,000||$29.47||$294,700.00||7,653|| |
|6/13/2016||Christopher M Griffith||VP||Sell||4,405||$30.16||$132,854.80||48,043|| |
|6/1/2016||Eugene A Bauer||Insider||Sell||2,500||$31.65||$79,125.00|| |
|6/1/2016||Thomas G Wiggans||CEO||Sell||11,000||$31.57||$347,270.00|| |
|5/2/2016||Eugene A Bauer||Insider||Sell||2,500||$25.09||$62,725.00|| |
|5/2/2016||Thomas G Wiggans||CEO||Sell||9,000||$25.11||$225,990.00|| |
|4/1/2016||Eugene A Bauer||Insider||Sell||2,500||$20.84||$52,100.00|| |
|4/1/2016||Thomas G Wiggans||CEO||Sell||7,000||$20.69||$144,830.00|| |
|3/1/2016||Eugene A Bauer||Insider||Sell||2,500||$22.55||$56,375.00|| |
|3/1/2016||Thomas G Wiggans||CEO||Sell||7,000||$22.57||$157,990.00|| |
|2/1/2016||Eugene A Bauer||Insider||Sell||2,500||$27.26||$68,150.00|| |
|2/1/2016||Thomas G Wiggans||CEO||Sell||9,000||$27.25||$245,250.00|| |
|1/4/2016||Eugene A Bauer||Insider||Sell||2,500||$33.17||$82,925.00|| |
|1/4/2016||Thomas G Wiggans||CEO||Sell||11,000||$33.17||$364,870.00|| |
|12/1/2015||Eugene A Bauer||Insider||Sell||2,500||$29.65||$74,125.00|| |
|11/2/2015||Eugene A Bauer||Insider||Sell||2,500||$27.82||$69,550.00|| |
|10/1/2015||Eugene A Bauer||Insider||Sell||2,500||$22.87||$57,175.00|| |
|9/14/2015||Eugene A Bauer||Insider||Sell||22,500||$28.05||$631,125.00|| |
|11/25/2014||Matthew K Fust||Director||Buy||6,000||$16.77||$100,620.00|| |
|10/8/2014||Bay City Capital Llc||Director||Buy||69,112||$16.00||$1,105,792.00|| |
Dermira (NASDAQ DERM) News Headlines
Dermira (NASDAQ:DERM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dermira (NASDAQ:DERM) Income Statement, Balance Sheet and Cash Flow Statement
Dermira (NASDAQ DERM) Stock Chart for Sunday, March, 18, 2018